With the emergence of molecular biomarkers, prostate cancer has entered a new era, according to Daniel P. Petrylak, MD, who added that DNA repair mutations, prostate-specific membrane antigen (PSMA), and androgen receptors have been shown to be versatile targets that are beneficial in terms of selecting optimal therapies.
Read the full article here.
source: Erica DiNapoli - OncLive